Results 1 to 10 of about 1,075 (125)

Estrogen associates with female predominance in Xp11.2 translocation renal cell carcinoma [PDF]

Scientific Reports, 2023
Based on the epidemiological characteristics of susceptibility and age selectivity for women in Xp11.2 translocation renal cell carcinoma (Xp11.2 tRCC), we inferred that estrogen was to be blamed. Rad54 like 2 (Rad54l2) which might be one of key effector
Yanwen Lu, Yiqi Zhu, Wenliang Ma, Ning Liu, Xiang Dong, Qiancheng Shi, Fei Yu, Hongqian Guo, Dongmei Li, Weidong Gan   +9 more
doaj   +2 more sources

Clinical and pathological heterogeneity of four common fusion subtypes in Xp11.2 translocation renal cell carcinoma [PDF]

Frontiers in Oncology, 2023
BackgroundXp11.2 translocation renal cell carcinoma (Xp11.2 tRCC) is a group of rare and highly heterogeneous renal cell carcinoma (RCC). The translocation involving TFE3 and different fusion partners lead to overexpression of the chimeric protein.
Wei Guo, Wei Guo, Yiqi Zhu, Xiaohong Pu, Hongqian Guo, Weidong Gan, Weidong Gan   +6 more
doaj   +2 more sources

Clinicopathologic, treatment and prognosis study of 46 Xp11.2 translocation/TFE3 gene fusion renal cell carcinomas [PDF]

BMC Urology, 2022
Purpose To report the clinicopathological features and mid- to long-term oncologic results of Xp11.2 translocation/transcription factor E3 (TFE3) gene fusion renal cell carcinomas (Xp11.2 translocation RCCs) in a single large-volume centrecentre. Methods
Jiale Zhou, Ling Zhao, Zhaolin Yang, Yonghui Chen, Xiaorong Wu, Wei Xue   +5 more
doaj   +2 more sources

Gene Expression Analysis of Aggressive Adult Xp11.2 Translocation Renal Cell Carcinoma at Clinical Stage T1N0M0 to Identify Potential Prognostic and Therapeutic Biomarkers

Biomedicines, 2022
Xp11.2 translocation renal cell carcinoma (tRCC), involving transcription factor E3 (TFE3) gene fusions, is a rare and aggressive RCC variant when present in adults and has been recently recognized as a unique entity in RCC.
Jee Soo Park, Myung Eun Lee, Won Sik Jang, Jongchan Kim, Se Mi Park, Won Sik Ham   +5 more
doaj   +1 more source

Both SUMOylation and ubiquitination of TFE3 fusion protein regulated by androgen receptor are the potential target in the therapy of Xp11.2 translocation renal cell carcinoma

Clinical and Translational Medicine, 2022
Background The aggressiveness of renal cell carcinoma (RCC) associated with Xp11.2 translocation/TFE3 gene fusion (Xp11.2 translocation RCC [Xp11.2 tRCC]) is age‐dependent, which is similar to the overall trend of reproductive endocrine hormones ...
Ning Liu, Yi Chen, Lei Yang, Qiancheng Shi, Yanwen Lu, Wenliang Ma, Xiaodong Han, Hongqian Guo, Dongmei Li,, Weidong Gan,   +9 more
doaj   +1 more source

Xp11.2 Translocation Renal Cell Carcinoma With TFE3 Rearrangement: Distinct Morphological Features and Prognosis With Different Fusion Partners

Frontiers in Oncology, 2021
BackgroundRenal cell carcinoma (RCC) associated with Xp11.2 translocation/TFE3 gene fusion is a rare and new subtype of RCC and was classified by the WHO in 2004. Since then, multiple 5′ fusion partners for TFE3 have been reported; however, the impact of
Yan Ge, Xingtao Lin, Qingling Zhang, Danyi Lin, Luqiao Luo, Huiling Wang, Zhi Li   +6 more
doaj   +1 more source

The incidence of renal cell carcinoma associated with Xp11.2 translocation/TFE3 gene fusion in Saudi adult patients with renal cancer: a retrospective tissue microarray analysis

Polish Journal of Pathology, 2019
Renal cell carcinoma (RCC) is the most common renal tumour. RCC with Xp11.2 translocation/TFE3 (transcription factor E3) gene fusions (Xp11.2 RCC) is positive for immunostain labelling by TFE3 antibody. This tumour is rarely described in adults.
Jaudah Al-Maghrabi, Shagufta Mufti, Wafaey Gomaa   +2 more
doaj   +1 more source

Are tumor-associated micro-angiogenesis and lymphangiogenesis considered as the novel prognostic factors for patients with Xp11.2 translocation renal cell carcinoma?

BMC Cancer, 2020
Background Tumor micro-angiogenesis and lymphangiogenesis are effective prognostic predictors in many solid malignancies. However, its role on Xp11.2 translocation RCC has not been fully elucidated.
Wenliang Ma, Jun Yang, Ning Liu, Xiaohong Pu, Feng Qu, Linfeng Xu, Xiaozhi Zhao, Xiaogong Li, Gutian Zhang, Hongqian Guo, Dongmei Li, Weidong Gan   +11 more
doaj   +1 more source

ANGPTL2‐mediated epigenetic repression of MHC‐I in tumor cells accelerates tumor immune evasion

Molecular Oncology, Volume 17, Issue 12, Page 2637-2658, December 2023., 2023
The ANGPTL2–α5β1‐integrin pathway in tumor cells accelerates polycomb repressive complex 2‐mediated repressive histone modification at the major histocompatibility complex class I (MHC‐I) promoter via JARID2 induction, thereby attenuating interferon γ‐induced MHC‐I expression in tumor cells.
Tsuyoshi Kadomatsu, Chiaki Hara, Ryoma Kurahashi, Haruki Horiguchi, Jun Morinaga, Keishi Miyata, Sohtaro Kurano, Hisashi Kanemaru, Satoshi Fukushima, Kimi Araki, Masaya Baba, W. Marston Linehan, Tomomi Kamba, Yuichi Oike   +13 more
wiley   +1 more source

A new risk-scoring system to predict Xp11.2 translocation renal cell carcinoma in adults

Journal of International Medical Research, 2021
Objective The objective was to derive and validate a practical scoring system for preoperative diagnosis of Xp11.2 translocation renal cell carcinoma (RCC) in adults.
Qiancheng Shi, Ning Liu, Yiqi Zhu, Feng Qu, Linfeng Xu, Xiaogong Li, Gutian Zhang, Hongqian Guo, Dongmei Li, Weidong Gan   +9 more
doaj   +1 more source